Marx Biotechnology Israeli Company

Marx Biotechnology (MBT) develops a blood test to diagnose the early onset of graft-versus-host disease (GVHD) in order to save lives, reduce costs, and improve patient care, allowing doctors to make quick, accurate, and efficient decisions on how best to manage and treat their patients. MBT's blood test will diagnose the early onset of GVHD by monitoring functions on a molecular level that have to change for the disease to occur. The test provides results to physicians within two hours.